StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)

Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –

BeOne Medicines operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BeOne Medicines's operating income for the twelve months ending Jun 30, 2026 was $923.10M. For fiscal 2025 it was $447.14M. The highest annual figure on record is $447.14M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$447.14M–
FY2024Dec 31, 2024-$568.20M–
FY2023Dec 31, 2023-$1.21B–
FY2022Dec 31, 2022-$1.79B–
FY2021Dec 31, 2021-$1.44B–
FY2020Dec 31, 2020-$1.66B–
FY2019Dec 31, 2019-$959.89M–
FY2018Dec 31, 2018-$705.77M–
FY2017Dec 31, 2017-$98.46M–
FY2016Dec 31, 2016-$117.06M–
FY2015Dec 31, 2015-$56.75M–
FY2014Dec 31, 2014-$15.76M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$325.05M+269.9%
Q1 FY2026Mar 31, 2026$249.90M+2151.0%
Q4 FY2025Dec 31, 2025$185.04M–
Q3 FY2025Sep 30, 2025$163.11M–
Q2 FY2025Jun 30, 2025$87.89M–
Q1 FY2025Mar 31, 2025$11.10M–
Q4 FY2024Dec 31, 2024-$79.43M–
Q3 FY2024Sep 30, 2024-$120.27M–
Q2 FY2024Jun 30, 2024-$107.16M–
Q1 FY2024Mar 31, 2024-$261.35M–
Q4 FY2023Dec 31, 2023-$383.80M–
Q3 FY2023Sep 30, 2023-$133.97M–
Q2 FY2023Jun 30, 2023-$318.72M–
Q1 FY2023Mar 31, 2023-$371.26M–
Q4 FY2022Dec 31, 2022-$468.62M–
Q3 FY2022Sep 30, 2022-$438.36M–
Q2 FY2022Jun 30, 2022-$439.40M–
Q1 FY2022Mar 31, 2022-$443.29M-731.8%
Q4 FY2021Dec 31, 2021-$571.74M–
Q3 FY2021Sep 30, 2021-$462.33M–
Q2 FY2021Jun 30, 2021-$474.84M–
Q1 FY2021Mar 31, 2021$70.17M–
Q4 FY2020Dec 31, 2020-$484.91M–
Q3 FY2020Sep 30, 2020-$440.14M–
Q2 FY2020Jun 30, 2020-$358.88M–
Q1 FY2020Mar 31, 2020-$373.76M–
Q4 FY2019Dec 31, 2019-$388.04M–
Q3 FY2019Sep 30, 2019-$312.27M–
Q2 FY2019Jun 30, 2019-$85.83M–
Q1 FY2019Mar 31, 2019-$173.76M–
Q4 FY2018Dec 31, 2018-$280.81M–
Q3 FY2018Sep 30, 2018-$151.10M-231.5%
Q2 FY2018Jun 30, 2018-$163.05M–
Q1 FY2018Mar 31, 2018-$110.81M–
Q4 FY2017Dec 31, 2017-$103.80M–
Q3 FY2017Sep 30, 2017$114.91M–
Q2 FY2017Jun 30, 2017-$58.02M–
Q1 FY2017Mar 31, 2017-$51.54M–
Q4 FY2016Dec 31, 2016-$37.27M–
Q3 FY2016Sep 30, 2016-$34.83M–

More BeOne Medicines figures

See a number that looks wrong?